Kadmon Holdings, Inc. announced that as previously announced, on August 13, 2020, the board of directors of the company appointed Nancy Miller-Rich to serve as a director on the Board until her successor is duly elected and qualified, or until her earlier death, resignation or removal. As of the date of her appointment to the Board, it had not yet been determined on which committees of the Board Ms. Miller-Rich would serve. On October 7, 2020, the Board appointed Ms. Miller-Rich to the Science and Technology Committee of the Board, effective immediately. In addition, the Board appointed Ms. Miller-Rich to serve, effective immediately, on the Belumosudil Launch Oversight Committee of the Board, a committee formed to oversee the potential launch of the company’s product candidate, belumosudil, the company's Rho-associated coiled-coil kinase 2 inhibitor. The company previously announced on September 30, 2020 the submission of a New Drug Application to the U.S. Food and Drug Administration for belumosudil for the treatment of patients with chronic graft-versus-host disease. The other members of the Board who serve on the Belumosudil Launch Oversight Committee are Cynthia Schwalm, who serves as the chair, and David E. Cohen.